Join Growin Stock Community!

Ge healthcare technologies inc.GEHC.US Overview

US StockHealthcare
(No presentation for GEHC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GEHC AI Insights

GEHC Overall Performance

GEHC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GEHC Recent Performance

-4.60%

Ge healthcare technologies inc.

0.05%

Avg of Sector

-0.31%

S&P500

GEHC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GEHC Key Information

GEHC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GEHC Profile

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Price of GEHC

GEHC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GEHC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
4.57
PE Ratio (TTM)
18.52
Forward PE
15.59
PS Ratio (TTM)
1.86
PB Ratio
3.69
Price-to-FCF
24.27
METRIC
VALUE
vs. INDUSTRY
Gross Margin
39.98%
Net Margin
10.11%
Revenue Growth (YoY)
4.85%
Profit Growth (YoY)
0.52%
3-Year Revenue Growth
4.89%
3-Year Profit Growth
5.38%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
4.57
PE Ratio (TTM)
18.52
Forward PE
15.59
PS Ratio (TTM)
1.86
PB Ratio
3.69
Price-to-FCF
24.27
Gross Margin
39.98%
Net Margin
10.11%
Revenue Growth (YoY)
4.85%
Profit Growth (YoY)
0.52%
3-Year Revenue Growth
4.89%
3-Year Profit Growth
5.38%

  • When is GEHC's latest earnings report released?

    The most recent financial report for Ge healthcare technologies inc. (GEHC) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GEHC's short-term business performance and financial health. For the latest updates on GEHC's earnings releases, visit this page regularly.

  • Where does GEHC fall in the P/E River chart?

    According to historical valuation range analysis, Ge healthcare technologies inc. (GEHC)'s current price-to-earnings (P/E) ratio is 18.07, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of GEHC?

    According to the latest financial report, Ge healthcare technologies inc. (GEHC) reported an Operating Profit of 827M with an Operating Margin of 14.51% this period, representing a growth of 3.25% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is GEHC's revenue growth?

    In the latest financial report, Ge healthcare technologies inc. (GEHC) announced revenue of 5.7B, with a Year-Over-Year growth rate of 7.13%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does GEHC have?

    As of the end of the reporting period, Ge healthcare technologies inc. (GEHC) had total debt of 10B, with a debt ratio of 0.27. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does GEHC have?

    At the end of the period, Ge healthcare technologies inc. (GEHC) held Total Cash and Cash Equivalents of 4.51B, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does GEHC go with three margins increasing?

    In the latest report, Ge healthcare technologies inc. (GEHC) achieved the “three margins increasing” benchmark, with a gross margin of 39.7%%, operating margin of 14.51%%, and net margin of 10.3%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess GEHC's profit trajectory and future growth potential.

  • Is GEHC's EPS continuing to grow?

    According to the past four quarterly reports, Ge healthcare technologies inc. (GEHC)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 1.29. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GEHC?

    Ge healthcare technologies inc. (GEHC)'s Free Cash Flow (FCF) for the period is 916M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 12.95% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of GEHC?

    The latest valuation data shows Ge healthcare technologies inc. (GEHC) has a Price-To-Earnings (PE) ratio of 18.07 and a Price/Earnings-To-Growth (PEG) ratio of -0.87. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.